{"id":"prednisone-and-belimumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Immunosuppression-related complications"},{"rate":null,"effect":"Corticosteroid-related side effects (hyperglycemia, osteoporosis, mood changes)"},{"rate":null,"effect":"Infusion reactions (belimumab)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisone is a corticosteroid that broadly dampens inflammatory and immune responses by binding glucocorticoid receptors and suppressing cytokine production and immune cell activation. Belimumab is a monoclonal antibody that specifically targets BLyS (also called BAFF), a key survival factor for B cells, thereby reducing pathogenic autoantibody-producing B cells. Together, this combination provides both broad immunosuppression and targeted B cell depletion.","oneSentence":"Prednisone suppresses immune responses through glucocorticoid receptor activation, while belimumab inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cell survival and antibody production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:02:16.809Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"}]},"trialDetails":[{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT07225387","phase":"PHASE4","title":"Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial","status":"RECRUITING","sponsor":"NephroNet, Inc.","startDate":"2024-10-01","conditions":"Lupus Nephritis","enrollment":30},{"nctId":"NCT03312907","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-01","conditions":"Systemic Lupus Erythematosus","enrollment":292},{"nctId":"NCT04629144","phase":"PHASE2","title":"Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-10-20","conditions":"Vasculitis, Cryoglobulinemia","enrollment":48},{"nctId":"NCT03967925","phase":"PHASE2","title":"Rituximab and Belimumab Combination Therapy in PR3 Vasculitis","status":"UNKNOWN","sponsor":"Rachel Jones","startDate":"2019-02-01","conditions":"ANCA Associated Vasculitis, Granulomatosis With Polyangiitis","enrollment":31},{"nctId":"NCT04660565","phase":"PHASE4","title":"Belimumab Treatment for IgG4-related Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-01","conditions":"IgG4-related Disease","enrollment":60},{"nctId":"NCT02260934","phase":"PHASE2","title":"Rituximab and Belimumab for Lupus Nephritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-07-09","conditions":"Lupus Nephritis","enrollment":43},{"nctId":"NCT01914770","phase":"","title":"Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Systemic Lupus Erythematosus","enrollment":1016}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":104,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Belimumab treatment"],"phase":"marketed","status":"active","brandName":"Prednisone and Belimumab","genericName":"Prednisone and Belimumab","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisone suppresses immune responses through glucocorticoid receptor activation, while belimumab inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cell survival and antibody production. Used for Systemic lupus erythematosus (SLE).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}